Essity B stock edges higher as Consumer Tissue sale plans and cautious analyst views shape valuation

Essity AB B stock (ISIN SE0009922164) is trading at 264.30 SEK on Cboe Europe as of September 16, 2026, just 3.16% below the average analyst price target of 272.13 SEK and reflecting investors' scrutiny of a potential sale of the Consumer Tissue business valued at 2.5-3.0 billion EUR.

Consumer Tissue sale plans drive valuation debate

According to Ad-hoc-news on September 16, 2026, media reports indicate that Essity is preparing a sale or spin-off of its Consumer Tissue division, with indicative valuation discussions in a range of 2.5-3.0 billion EUR for the business.

As Placera reported on September 16, 2026, the magazine Affarsvarlden judges that this indicative price tag is on the low side, and calculates that the remaining Essity group would then be valued at roughly 12-13 times EV/EBIT if operations develop in line with consensus forecasts.

According to Zonebourse on September 16, 2026, Affarsvarlden remains cautious on Essity stock, arguing that at first glance there is limited upside left if Consumer Tissue is sold at the discussed valuation and the rest of the business trades at that 12-13 times EV/EBIT multiple.

Stock price, targets and market positioning

Zonebourse data on September 16, 2026 show Essity B stock quoted at 264.30 SEK in Cboe Europe trading, compared with a previous closing price of 263.80 SEK, corresponding to a modest daily increase of 0.19% and underscoring a relatively stable market reaction to the restructuring speculation.

According to Zonebourse, the average analyst price target for Essity B stock currently stands at 272.13 SEK, so the current price of 264.30 SEK is about 3.16% below this consensus target, giving investors a limited but visible potential upside versus the analyst view.

In the same overview, Zonebourse lists Essity B as a constituent of the OMX Stockholm 30 index and highlights that the shares have gained 0.34% over the past five trading days but are down 0.45% year-to-date, showing that recent performance has mildly improved while the longer-term trend since the start of 2026 remains slightly negative.

Latest reported figures and earnings outlook

According to the agenda section in Zonebourse, Essity plans to publish its results for the third quarter of 2026 on October 22, 2026, a date that will be closely watched for confirmation of margin trends after the Consumer Tissue sale discussions.

While the week-filtered search set does not surface a detailed breakdown of Essity's most recent quarterly revenue and earnings lines, Affarsvarlden's analysis reported via Placera explicitly bases its 12-13 times EV/EBIT calculation on consensus expectations for future operating results, indicating that the market currently assumes a stable development of Essity's underlying hygiene and health product operations.

From an investor perspective, the key fundamental question for the coming quarters is how the potential separation of Consumer Tissue would affect Essity's earnings mix and margin profile, since selling a lower-margin division at 2.5-3.0 billion EUR could support a higher EV/EBIT multiple for the remaining business if management can sustain or improve EBIT through focus on higher-value segments.

Risk factors and analyst stance

Affarsvarlden's cautious stance, as summarized by Zonebourse, highlights the risk that the Consumer Tissue transaction could crystallize value at a level that leaves little room for additional share-price appreciation once the deal is completed, particularly if execution or market conditions deviate from consensus assumptions.

According to Placera, Affarsvarlden currently refrains from issuing a fresh recommendation on Essity stock, preferring to wait for clearer details on the Consumer Tissue process and on how management intends to use potential proceeds, for example for debt reduction, selective acquisitions or shareholder returns.

For investors, the main counter-factor to the restructuring upside is therefore the risk of a lower-than-expected sale price, combined with possible short-term volatility in earnings during the transition, even though the long-term thesis of focusing on higher-margin hygiene and health products remains intact.

Essity B stock price snapshot

Essity B stock is quoted at 264.30 SEK on Cboe Europe as of September 16, 2026, with the previous close at 263.80 SEK and a daily change of 0.19% in that venue; this price level sits approximately 3.16% below the consensus target of 272.13 SEK and reflects a moderate discount to analyst expectations rather than a deep value gap.

More news and analyses on Essity B stock